A Study Of The Efficacy And Safety Of Adjuvant Autogene Cevumeran Plus Atezolizumab And Mfolfirinox Versus Mfolfirinox Alone In Participants With Resected Pancreatic Ductal Adenocarcinoma (Imcode003)
Posted Date: Apr 25, 2024
- Investigator: Davendra Sohal
- Specialties: Cancer, Pancreatic Cancer
- Type of Study: Drug
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Criteria:
Null
Keywords:
Resected
For More Information:
Andrea Ordonez
NULL
cancer@uchealth.com